{
    "title": "112_hr6502",
    "content": "The Act titled \"Life-Threatening Diseases Compassion through Combination Therapy Act of 2012\" promotes the development of combinations of investigational new drugs for serious diseases by providing marketing exclusivity and priority review for significant drug combinations. The Act \"Life-Threatening Diseases Compassion through Combination Therapy Act of 2012\" allows the Secretary to designate a combination of drugs as significant if they have the potential to advance treatment for serious diseases. The Act allows the Secretary to designate drug combinations meeting specific criteria for codevelopment, including at least 2 unapproved drugs. The Secretary can designate drug combinations under section 351 of the Public Health Service Act to encourage codevelopment. Recommendations from the codevelopment task force are considered, and manufacturers can request the Secretary to determine eligibility. The Secretary can designate drug combinations under section 351 of the Public Health Service Act to encourage codevelopment. Manufacturers may request the Secretary to determine if a combination of 2 or more drugs is significant, and the Secretary must respond within 30 days. The Secretary can designate drug combinations as significant under section 351 of the Public Health Service Act to promote codevelopment. If a combination of drugs meets the requirements for designation, the Secretary will notify the requester within 30 days. The Secretary can designate drug combinations as significant under section 351 of the Public Health Service Act to promote codevelopment. If a combination of drugs does not meet the requirements for designation, the Secretary will notify the requester that it is not a significant drug combination. The Secretary can designate drug combinations as significant under section 351 of the Public Health Service Act to promote codevelopment. A request for designation must be made concurrently with or after submitting an application for drug investigation. The deadline for this request is not later than the completion of phase I trials for any of the drugs involved in the combination. A list of significant drug combinations will be provided within 180 days. The Secretary will develop and publish an initial list of significant drug combinations within 180 days of the enactment of the Act. This list will be updated annually to include additional drug combinations designated as significant. The Secretary will designate significant drug combinations and exclude those no longer meeting requirements. Market exclusivity may be extended prior to drug approval under section 505(b). The Secretary can extend market exclusivity by 6 months for a significant drug combination under section 505(b), excluding certain approvals. The Secretary can extend market exclusivity by 6 months for a significant drug combination under section 505(b), excluding certain approvals for supplements or subsequent applications by the same sponsor or manufacturer. The Secretary can extend market exclusivity for a significant drug combination under section 505(b) for specific changes or modifications to the drug, including new indications, routes of administration, dosing schedules, dosage forms, delivery systems, devices, or strengths. This does not apply to changes in the drug's structure that do not affect safety or effectiveness. The Secretary can extend market exclusivity for a significant drug combination under section 505(b) for specific changes or modifications to the drug, including new indications, routes of administration, dosing schedules, dosage forms, delivery systems, devices, or strengths. This does not apply to changes in the drug's structure that do not affect safety or effectiveness. If a drug is designated as a significant drug combination, the Secretary must review and take action on any application for such drug within 6 months. The definition of \"significantly advance treatment\" for a drug combination includes treating life-threatening or serious diseases with no existing therapy available. The drug combination must demonstrate improved effects on serious outcomes of a disease compared to alternative therapies, such as superiority or minimizing drug resistance, in a clinical trial assessing serious morbidity. The Fast Track Product designation under the Federal Food, Drug, and Cosmetic Act is amended to include drugs in significant combinations designated under section 505E(a) for the treatment of serious or life-threatening conditions with unmet medical needs. The Fast Track Product designation is amended to include drugs in significant combinations designated for serious or life-threatening conditions with unmet medical needs. A Codevelopment Task Force is established. The Secretary of Health and Human Services will establish an interagency task force within 6 months of this Act to promote codevelopment of drugs in significant combinations for serious or life-threatening diseases like cancer. Task force membership will include experts in research and drug development. The task force's duties include recommending a list of significant drug combinations. The interagency task force, established by the Secretary of Health and Human Services, will recommend a list of significant drug combinations for serious or life-threatening diseases like cancer. The task force will develop and make publicly available a list of recommended drug combinations for designation under the Federal Food, Drug, and Cosmetic Act. Members of the public will have the opportunity to comment on the list. The interagency task force, established by the Secretary of Health and Human Services, will recommend a list of significant drug combinations for serious or life-threatening diseases like cancer. The task force will revise the list in response to public comments and provide updates annually to the Secretary and Congress. The interagency task force will recommend significant drug combinations for serious diseases like cancer, updating the list annually and submitting a policy report to the Secretary and Congress. The interagency task force will recommend significant drug combinations for serious diseases like cancer, updating the list annually and submitting a policy report to the Secretary and Congress. The report contains recommendations for policy changes to support the codevelopment of drugs in significant combinations. Before submission, the task force will seek public comments. The task force will draft a report on significant drug combinations for serious diseases, seeking public comments before submission. FACA does not apply to the task force's duration. A significant drug combination is defined as a combination of 2 or more drugs with potential benefits when used together. The task force will draft a report on significant drug combinations for serious diseases, seeking public comments before submission. A significant drug combination is defined as a combination of 2 or more drugs with potential benefits when used together, meeting specific criteria for codevelopment as outlined by the FDA. The task force will draft a report on significant drug combinations for serious diseases, seeking public comments before submission. Significant drug combinations are defined as combinations of 2 or more drugs with potential benefits when used together, meeting specific criteria for codevelopment as outlined by the FDA. U.S.C. 355) or licensed under section 351 of the Public Health Service Act (42 U.S.C. 262). SEC. 4. STUDY. The Secretary of Health and Human Services will conduct a study on the impact of exclusivity extensions on drug combinations. Interim findings will be shared with a task force and the public for comments. Final findings must be provided within 5 years. Final Findings: The Secretary will submit the study findings to Congress within 5 years of enacting the Act, following a comment period."
}